Sonelokimab

Names

[ Name ]:
Sonelokimab

Biological Activity

[Description]:

Sonelokimab (ALX 0761; M 1095) is a trivalent nanobody comprised of monovalent camelid-derived nanobodies specific to human interleukin (IL)-17A, IL-17F, and human serum albumin VHHs. Sonelokimab has the potential for plaque-type psoriasis research[1][2].

[Related Catalog]:

Signaling Pathways >> Immunology/Inflammation >> Interleukin Related

Research Areas >> Inflammation/Immunology

[Target]

IL-17A

IL-17F

[References]

[1]. Kim A Papp, et al. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. Lancet. 2021 Apr 24;397(10284):1564-1575.

[2]. Martin A Rossotti, et al. Immunogenicity and humanization of single-domain antibodies. FEBS J. 2022 Jul;289(14):4304-4327.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.